Marc Comas – Managing Director, Accord Healthcare Iberia

Accord’s Marc Comas highlights the company’s presence in Spain with leading oncology products, three biosimilars and investment in specialty pharma. He shares his views on the COVID pandemic, the future of the supply chain, the importance of Spain, Barcelona’s attractiveness for the pharma industry, and explains why Accord will be able to compete on price due to its in-house manufacturing capabilities.  
Accord recognises biosimilars as a future growth driver for the company. It is common sense as medicine moves to biologics and biologics move toward gene and cell therapy.
Become a PharmaBoardroom Member for free to access this content
Join the 35,000+ pharmaceutical professionals who already subscribe to PharmaBoardroom
Already a member? Sign In

Related Interviews

Latest Report